Welcome to our dedicated page for Intuitive Surgical SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intuitive Surgical, Inc. (ISRG) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer headquartered in Sunnyvale, California, Intuitive uses these filings to report financial results, material events, and other information relevant to shareholders and regulators.
Among the key documents available are current reports on Form 8-K. Recent 8-K filings include items reporting quarterly financial results under Item 2.02, where Intuitive furnishes press releases detailing revenue, procedure growth on its da Vinci surgical systems and Ion endoluminal system, and changes in the installed base of systems. Another 8-K filing reports a change in the role of a senior executive under Item 5.02, illustrating how the company discloses updates related to its leadership structure.
Investors also use Intuitive’s SEC filings to follow information that may appear in annual reports on Form 10-K and quarterly reports on Form 10-Q, such as risk factor discussions, descriptions of the company’s business and technologies, and summaries of regulatory and market conditions affecting robotic-assisted surgery and minimally invasive care. While these specific forms are not reproduced in the provided excerpts, they are part of the broader filing set accessible through the SEC’s EDGAR system.
On Stock Titan, ISRG filings are paired with AI-powered summaries designed to explain the content and context of complex documents. These tools can help readers understand the significance of earnings releases, regulatory updates, or governance changes without reading every line of each filing. Users can also review filings that relate to financial reporting, such as exhibits containing press releases, and monitor how Intuitive communicates procedure trends, system placements, and other operational metrics to the market.
For investors researching Intuitive’s regulatory history, this page serves as a focused entry point to the company’s SEC disclosures, including 8-Ks that reference earnings announcements and other material developments.
Intuitive Surgical SVP and Chief Manufacturing and Supply Chain Officer Mark Brosius reported equity vesting and related tax withholdings. On February 28, 2026, 8,378 performance stock units granted on February 28, 2023 and 877 restricted stock units granted on February 28, 2022 converted into common stock.
In connection with these settlements, 435 and 4,155 shares of common stock were withheld at a price of $503.51 per share to cover tax liabilities and exercise costs. After these transactions, Brosius directly owned 6,564 shares of Intuitive Surgical common stock.
Myriam Curet McAdams filed a Form 144 reporting proposed and recent sales of Common stock of ISRG. The filing shows a proposed sale of 125 shares via a stock option exercise on 03/02/2026 for cash.
The filing also lists several sales by the same holder in the prior three months, including 2,345 shares on 02/27/2026 (1171819.95), 421 shares on 02/11/2026 (208378.16), and 105 shares on 02/10/2026 (51938.25).
Intuitive Surgical EVP & Chief Medical Officer Myriam Curet reported multiple equity award transactions involving performance stock units (PSUs), restricted stock units (RSUs), and common stock. PSUs initially granted on February 28, 2023 had their performance criteria certified, and the resulting PSUs vested on February 28, 2026, converting into common shares.
On the same date, RSUs also vested and converted one-for-one into common stock. Some of the newly delivered shares were withheld to cover statutory tax obligations related to the PSU and RSU settlements, using shares valued at about $503.51 per share. In a separate move on February 27, 2026, a trust associated with Curet sold 2,345 shares of Intuitive Surgical common stock at an average price of $499.71 per share under a pre-arranged Rule 10b5-1 trading plan that expires on July 29, 2026.
Intuitive Surgical senior executive Patricia L. Wadors reported mixed equity transactions. She sold 220 shares of common stock in an open-market sale at $499.71 per share under a Rule 10b5-1 trading plan that expires on June 5, 2026. In connection with RSUs vesting, 458 shares were delivered, with 238 shares withheld at $506.17 per share to cover taxes. She also received a new grant of 3,584 restricted stock units that vest 25% annually over four years, each RSU representing one share of common stock upon vesting.
Fredrik Widman reported a Form 144 sale notice for 133 common shares of ISRG sold on 02/11/2026 for $65,829.68.
The filing lists restricted stock activity and a separate entry showing 249 units dated 02/26/2026; the primary disclosed sale was the 133-share transaction.
Myriam Curet McAdams notified a proposed sale of 2,345 common shares under a Form 144 filing. The filing lists the securities as restricted stock to be sold through Morgan Stanley Smith Barney LLC on 02/26/2026.
The filing also discloses multiple recent open-market dispositions by the same holder: 421 shares on 02/11/2026, 105 shares on 02/10/2026, 126 shares on 01/29/2026, 230 shares on 01/27/2026, 104 shares on 12/10/2025, and 125 shares on 12/01/2025, each with the reported transaction proceeds in dollars.
Intuitive Surgical SVP Iman Jeddi reported multiple equity compensation transactions dated February 26, 2026. He was granted 2,793 performance stock units originally awarded on February 28, 2023, after the Compensation Committee confirmed performance goals were achieved; these PSUs vest on February 28, 2026, subject to continued service. He also received a new grant of 4,480 restricted stock units that vest 25% annually over four years. Previously granted RSUs converted into 1,622 and 687 shares of common stock on a one-for-one basis as they vested, with 631 and 341 shares of common stock withheld at a price of $506.17 per share to cover statutory tax obligations. Following these transactions, he holds direct common stock and derivative awards, and 26,649 additional common shares are held indirectly by a trust.
Intuitive Surgical executive Henry L. Charlton reported multiple equity awards and share settlements related to prior grants. On February 26, 2026, he received 3,591 performance stock units granted in 2023 and 4,032 new restricted stock units, all at a stated price of $0.00 per unit.
On the same date, 1,717 and 1,030 restricted stock units converted into common stock, while 765 and 459 common shares were withheld to cover tax obligations tied to these vestings. Following these transactions, he directly held 5,220 shares of Intuitive Surgical common stock.
Intuitive Surgical EVP & CFO Jamie Samath reported multiple equity-compensation transactions in company stock. He received a grant of 3,591 performance stock units originally awarded on February 28, 2023, after performance criteria were certified, and 6,720 new restricted stock units granted on February 26, 2026. In addition, 1,908 and 1,488 restricted stock units from prior awards converted into common shares at no cash cost, reflecting scheduled vesting. To cover statutory tax withholding on these vestings, 900 and 738 common shares were withheld and delivered for taxes, leaving the remaining net shares in his account.